Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show

SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer. The company’s ongoing research places them at the vanguard of metabo-oncology, an emerging field of cancer research that focuses on the role metabolic hormones play in the development and progression of many common cancers, as well as tumor resistance developed in response to certain treatment.

Read More

Co-Founder and Chief Business Officer James Shanahan Discusses Metabo-Oncology and Breast Cancer

Read More

AACR 2020: SynDevRx Selected to Present the Results from its Phase 1 Study of SDX-7320 in Late-Stage Cancer Patients

SynDevRx recently completed a Phase 1 study in late-stage cancer patients with a variety of solid tumors. The initial results from the clinical study were selected by AACR for presentation by one of the Principle Investigators – Dr. Monica Mita, MD. Dr. Mita is a Professor of Medicine, Co-Director, Experimental Therapeutics Program at Cedars-Sinai Medical […]

Read More

SynDevRx launches Metabo-Oncology.com website

Metabo-Oncology press release 26Mar 2019 FINAL

Read More

Preclinical activity of SDX-7320 in mouse models of obesity and obesity-driven cancer

Cancer patients who are obese face a greater risk of dying from cancer compared to non-obese patients (Calle, 2003). Excess visceral adiposity is believed to contribute to metastasis and progression of cancer via multiple mechanisms: increased secretion of the adipose tissue hormone leptin, decreased secretion of adiponectin, increased production of estrogen in adipose tissue, and elevated insulin (secondary to peripheral insulin resistance) as well as the local effects of inflammatory cytokines (Gucalp, 2016).

Read More

SynDevRx will be attending ASCO (Chicago) June 3–7

The ASCO Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.

Read More